KCNK3: New gene target for pulmonary hypertension?

Expert Review of Respiratory Medicine

Volumn 8, Issue 4, 2014, Pages 385-387

  Girerd, Barbara ^a,b,c   Perros, Frédéric ^a,b,c   Antigny, Fabrice ^a,b,c   Humbert, Marc ^a,b,c   Montani, David ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Ion channel; KCNK3 gene; Pulmonary arterial hypertension; Respiratory; TASK1

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; POTASSIUM CHANNEL; NERVE PROTEIN; POTASSIUM CHANNEL SUBFAMILY K MEMBER 3; TANDEM PORE DOMAIN POTASSIUM CHANNEL;

AUTOSOMAL DOMINANT DISORDER; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; KCNK3 GENE; LINKAGE ANALYSIS; LUNG ARTERY PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM CHANNELOPATHY; PULMONARY HYPERTENSION; REVIEW; GENETIC PREDISPOSITION; GENETICS; MUTATION;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; MUTATION; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN;

EID: 84904283068     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.909731     Document Type: Review

References (30)

1. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med 1954;30(3): 195-207
2. Austin ED, Loyd JE. Heritable forms of pulmonary arterial hypertension. Semin Respir Crit Care Med 2013;34(5): 568-80
3. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl):S32-42
4. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369(4): 351-61
5. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26(1): 81-4
6. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67(3): 737-44
7. Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186(9): 892-6
8. Girerd B, Montani D, Eyries M, et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010;11: 73
9. Chaouat A, Coulet F, Favre C, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004;59(5): 446-8
10. Shintani M, Yagi H, Nakayama T, et al. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009;46(5): 331-7
11. Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011;32(12): 1385-9
12. Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012;5(3): 336-43
13. Bittner S, Meuth SG. Targeting ion channels for the treatment of autoimmune neuroinflammation. Ther Adv Neurol Disord 2013;6(5): 322-36
14. Tang Y, Stahl-Herz J, Sampson BA. Molecular diagnostics of cardiovascular diseases in sudden unexplained death. Cardiovasc Pathol 2014;23(1): 1-4
15. Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 2012;45(15): 1132-44
16. Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am J Physiol Renal Physiol 2000;279(5):F793-801
17. Olschewski A, Li Y, Tang B, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006;98(8): 1072-80
18. Hartness ME, Lewis A, Searle GJ, et al. Combined antisense and pharmacological approaches implicate hTASK as an airway O(2) sensing K(+) channel. J Biol Chem 2001;276(28): 26499-508
19. Osipenko ON, Evans AM, Gurney AM. Regulation of the resting potential of rabbit pulmonary artery myocytes by a low threshold, O2-sensing potassium current. Br J Pharmacol 1997;120(8): 1461-70
20. Tang B, Li Y, Nagaraj C, et al. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2009;41(4): 476-83
21. Seyler C, Duthil-Straub E, Zitron E, et al. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation. Br J Pharmacol 2012;165(5): 1467-75
22. Trapp S, Aller MI, Wisden W, Gourine AV. A role for TASK-1 (KCNK3) channels in the chemosensory control of breathing. J Neurosci 2008;28(35): 8844-50
23. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J 2012;39(2): 329-43
24. Machado RD. Seeking the right targets: gene therapy advances in pulmonary arterial hypertension. Eur Respir J 2012;39(2): 235-7
25. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372(9640): 719-27
26. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67(1): 12-18
27. Noel S, Dhooghe B, Leal T. PDE5 inhibitors as potential tools in the treatment of cystic fibrosis. Front Pharmacol 2012;3: 167
28. Frump AL, Lowery JW, Hamid R, et al. Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension. PLoS One 2013;8(11):e80319
29. Drake KM, Dunmore BJ, McNelly LN, et al. Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013;49(3): 403-9
30. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol 2013. [Epub ahead of print]